HCV infection in haemodialysed patients: A role for serum IL-10 and TGF-β1 in liver damage?

被引：5
作者：
Burra, P. [1 ]
Masier, A. [1 ]
Morisco, F. [5 ]
Di Leo, V. [1 ]
Zorzi, M. [4 ]
Senzolo, M. [1 ]
Marchini, F. [2 ]
Guido, M. [3 ]
Canova, D. [1 ]
Floreani, A. [1 ]
Burroughs, A. K. [6 ]
机构：
[1] Univ Padua, Dept Surg & Gastroenterol Sci, Gastroenterol Sect, I-35128 Padua, Italy
[2] Univ Padua, Dept Nephrol, I-35128 Padua, Italy
[3] Univ Padua, Dept Pathol, I-35128 Padua, Italy
[4] Ist Oncol Veneto, Venetian Tumor Registry, Veneto, Italy
[5] Cardarelli Hosp, Liver Physiopathol Div, Naples, Italy
[6] Royal Free Hosp, Liver Transplantat & Hepatobiliary Med Unit, London NW3 2QG, England
来源：
DIGESTIVE AND LIVER DISEASE | 2008年 / 40卷 / 10期
关键词：
HCV; Haemodialysis; IL-10; TGF-beta(1);
D O I：
10.1016/j.dld.2008.01.022
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Background. Hepatitis C virus (HCV) infection is often clinically silent in haemodialysed (HD) patients and their immune response may modulate liver damage in HCV infection. IL-10 and TGF-beta(1), could play a role in this setting as, IL-10 down-regulates hepatic fibrosis, while TGF-beta(1), is a pro-fibrotic cytokine. Aim. To evaluate the role of IL-10 and TGF-beta(1) in HD/HCV+ patients. Patients. 71 HD/HCV+ patients (58 with normal [HD/HCV-N] and 13 with high serum transaminases [HD/HCV-H]), 40 non-uremic patients with chronic hepatitis C (HCV+), 56 HD anti-HCV- patients and 20 healthy volunteers (H). Methods. IL-10 and TGF-beta(1) serum levels were assessed using ELISA tests. Liver histology was assessed by Ishak's score. Results. IL-10 serum levels were significantly higher in HD patients, both HCV+ (3.7 +/- 0.4 pg/ml; p < 0.01) and HCV- (3.8 +/- 0.8 pg/ml; p < 0.05) than in non-uremic HCV patients (2.3 +/- 0.4 pg/ml). Among the HD/HCV+ patients, IL-10 serum levels were similar in HD/HCV-N and in HD/HCV-H patients. Among the HD/HCV+ patients, IL-10 serum levels were similar in those with moderate histological damage compared to those with mild damage. TGF-beta(1) serum levels were significantly lower in HD patients, both HCV+ (4.6 +/- 0.9 ng/ml) and HCV-(6.0 +/- 0.9 ng/ml) than in non-uremic HCV+ patients (8.1 +/- 1.1 ng/ml; p < 0.001 and p < 0.01, respectively), but similar to the values found in H (5.3 +/- 0.9 ng/ml; p=n.s.). No correlation was seen between IL-10 and TGF-beta(1) serum levels in any of the groups considered. Conclusions. Patients on haemodialysis treatment to have high levels of IL-10, which remain high even when patients are anti-HCV+, whereas the opposite is true of TGF-beta(1). The cytokine pattern observed in HD patients is compatible with the hypothesis explaining the relatively benign evolution of HCV-related liver disease in HD patients, and has a pathophysiological role. (c) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：827 / 833
页数：7
相关论文
共 43 条
  • [11] Cohen G, 1997, KIDNEY INT, V52, pS79
  • [12] *COMM AISF, 2002, PORT HCV CON TRANS N
  • [13] DESCAMPSLATSCHA B, 1993, KIDNEY INT, V43, pS135
  • [14] Espinosa M, 2000, CLIN NEPHROL, V54, P151
  • [15] Espinosa M, 2002, CLIN NEPHROL, V58, P143
  • [16] Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients
    Espinosa, M
    Martin-Malo, A
    de Lara, MAA
    Ajama, P
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (08) : 1669 - 1674
  • [17] Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients
    Fabrizi, F
    Lunghi, G
    Andrulli, S
    Pagliari, B
    Mangano, S
    Faranna, P
    Pagano, A
    Locatelli, F
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (07) : 1394 - 1398
  • [18] Molecular aspects of T- and B-cell function in uremia
    Girndt, M
    Sester, M
    Sester, U
    Kaul, H
    Köhler, H
    [J]. KIDNEY INTERNATIONAL, 2001, 59 : S206 - S211
  • [19] Uremia-associated immune defect:: The IL-10-CRP axis
    Girndt, M
    Ulrich, C
    Kaul, H
    Sester, U
    Sester, M
    Köhler, H
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S76 - S79
  • [20] The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients
    Girndt, M
    Sester, U
    Sester, M
    Deman, E
    Ulrich, C
    Kaul, H
    Köhler, H
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (06) : 2385 - 2391
12345